UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit

Rhea-AI Summary

UroGen Pharma (Nasdaq: URGN), a biotech firm focused on urothelial and specialty cancers, will participate in a virtual fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit. The event is scheduled for May 28, 2024, at 3:20 PM ET. Investors can access a live webcast through the company's website. This event presents an opportunity for UroGen to discuss its innovative cancer treatments and engage with stakeholders.

Positive

• UroGen Pharma's participation in a high-profile oncology summit enhances visibility and credibility within the biotech sector.
• The fireside chat provides a platform for UroGen to showcase their innovative cancer treatments to potential investors and industry experts.
• Live webcast availability allows broader access and engagement from global stakeholders.

Negative

• The press release lacks detailed financial or clinical data updates, leaving investors with actionable information.
• Potential investor frustration due to minimal tangible information on business development or future projections.

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will participate in a virtual fireside chat at the TD Cowen 5^th Annual Oncology Innovation Summit on Tuesday, May 28, 2024 at 3:20 PM ET.

A live webcast of the fireside chat can be accessed by visiting the Events and Presentations Section of the Company’s website: https://investors.urogen.com

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. To learn more, visit www.UroGen.com or follow us on X (Twitter), @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522560591/en/

INVESTOR CONTACT:

Vincent Perrone

Senior Director, Investor Relations

vincent.perrone@urogen.com

609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano

Director, Corporate Communications

cindy.romano@urogen.com

609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.

FAQ

What is UroGen Pharma's stock symbol?

UroGen Pharma's stock symbol is URGN.

When will UroGen Pharma participate in the TD Cowen 5th Annual Oncology Innovation Summit?

UroGen Pharma will participate on May 28, 2024, at 3:20 PM ET.

How can I access the live webcast of UroGen Pharma's fireside chat?

You can access the live webcast on UroGen Pharma's website in the Events and Presentations section.

What will UroGen Pharma discuss at the Oncology Innovation Summit?

UroGen Pharma will discuss their innovative solutions for treating urothelial and specialty cancers.

Why is UroGen Pharma's participation in the Oncology Innovation Summit significant?

Participation enhances UroGen Pharma's visibility and credibility in the biotech sector and allows them to engage with potential investors and industry experts.